In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Ticagrelor reduces ischaemic events in diabetes patients with prior coronary intervention

THEMIS-PCI study presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Interventional Cardiology and Cardiovascular Surgery


Paris, France – 1 Sept 2019: Ticagrelor reduces ischaemic events in patients with diabetes and previous percutaneous coronary intervention (PCI), according to late breaking results from the THEMIS-PCI study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology(1) and published in The Lancet(2). 

Senior author Professor Philippe Gabriel Steg of Hospital Bichat, Paris, France said: “Treatment with ticagrelor and aspirin also increased major bleeding relative to aspirin alone, but there was a net clinical benefit with dual antiplatelet therapy.”

Patients with diabetes represent 25–35% of those undergoing PCI, making it a sizeable population. Dual antiplatelet therapy is administered immediately following PCI, but in the long-term, patients are generally treated with a single antiplatelet agent (usually aspirin).

THEMIS-PCI is a prespecified subgroup analysis of the THEMIS trial, also presented today at ESC Congress. The THEMIS trial investigated whether adding the antiplatelet drug ticagrelor to low-dose aspirin would reduce the risk of thrombotic events in patients aged 50 or older with type 2 diabetes and stable coronary artery disease (defined as a history of PCI, bypass grafting, or angiographic stenosis of 50% or more in at least one coronary artery). Patients with known prior myocardial infarction or stroke were excluded.

THEMIS enrolled 19,220 patients at 1,315 sites across 42 countries in North America, South America, Asia, Africa, Australia, and Europe. Of those, 11,154 patients (58%) had undergone PCI and were included in the THEMIS-PCI study.

“We hypothesised that the efficacy, safety and net clinical benefit of ticagrelor may be different in the subgroup of patients with a history of PCI, who have previously been exposed to dual antiplatelet therapy with aspirin and a P2Y12 inhibitor such as ticagrelor, prasugrel or clopidogrel,” noted Prof Steg.

Participants were randomly allocated to ticagrelor versus placebo, both on top of aspirin. The primary efficacy outcome was the composite of cardiovascular death, heart attack, or stroke. The primary safety outcome was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. The median follow-up was 39.9 months.

Ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, (the relative reduction was 15% in patients with prior PCI, p = 0.013) although with a doubling of major bleeding (p<0.0001).  The net clinical benefit appeared more favourable in patients with previous PCI than in patients without previous PCI, when evaluated as the composite of efficacy events and bleedings (15% relative risk reduction versus 6% relative risk increase, significant interaction, p = 0.012).

Prof Steg said: “The results suggest that long-term therapy with ticagrelor in addition to aspirin may be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy and have high ischaemic risk and low bleeding risk. This is a novel therapeutic option for a large and easy to identify patient population.”

ENDS

Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding:  The study was funded by AstraZeneca.

Disclosures:  Professor Philippe Gabriel Steg discloses the following relationships: Research grant from Amarin, Bayer, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Idorsia, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi, Servier.

References and notes

(1) THEMIS-PCI will be discussed during:

(2) The full paper will be available during Congress from press@escardio.org

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.